• Contact Us
  • International
  • United States

Baroreflex Activation Therapy (BAT) for Resistant Hypertension & Heart Failure

  • Home
  • Company Overview
  • Board of Directors
  • Senior Management
  • Newsroom
    • News Release
    • In the News
    • Media Kit
    • Image Library
    • Media Contacts
  • Recent Publications

Home / Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Posted on August 13, 2012 in Publication

Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. J Am Soc Hypertens. 2012;6(2):152-158. View article

 
  • AdvaMed Code of Ethics
cvrx.com

©2013 CVRx. All Rights Reserved.

CAUTION: The CVRx Barostim neo™ System is CE Marked and approved for sale for hypertension patients in Europe. CVRx Barostim neo™ System is an investigational device and is limited by United States law to investigational use. Exclusively for Clinical Investigations for the treatment of heart failure.